title: Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor].
authors.affiliation: Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
authors.forename: Kyu Yong
authors.initials: KY
authors.lastname: Cho
authors.forename: Hideaki
authors.initials: H
authors.lastname: Miyoshi
authors.forename: Akinobu
authors.initials: A
authors.lastname: Nakamura
authors.forename: Takashi
authors.initials: T
authors.lastname: Kurita
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Atsumi
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000172:deficiency*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004700:Endocrine System Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D005260:Female; D030342:Genetic Diseases, Inborn / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000175:diagnosis*; D007010:Hyponatremia / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000077594:Nivolumab; D000324:Adrenocorticotropic Hormone